NCT07685353 Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
| NCT ID | NCT07685353 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Condition | Chronic Liver Disease and Cirrhosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-07-07 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-07-07 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression. Genetic and epidemiological studies, indicates strong heritability of hepatic fat content.Family studies demonstrate that first degree relatives of patients with MAFLD are at a much higher risk of the disease than the general population.Most of the data available is regarding Deceased Donor Liver Transplant and Western population.Most studies have studied single gene variant but fatty liver is a polygenic trait.No study was done exclusively in MASH recipients. In this study we aim to study the effect of recipient and donor PNPLA3, MBOAT7 gene variations, and other clinical \& laboratory data on graft liver steatosis in liver transplant recipients. We also propose to compare the outcomes of genetically related donors vs unrelated donors, to know the influence of genetic factors vis-a-vis environmental factors.
Eligibility Criteria
Inclusion Criteria: * All LDLT recipients with MASH related CLD and their donors who underwent their surgery at ILBS at least 3 years prior to the onset of this study. Exclusion Criteria: * Pediatric (\<18 years) * Transplants for ALF/ ACLF
Contact & Investigator
Viniyendra Pamecha, MS, FEBS
STUDY DIRECTOR
Institute of Liver and Biliary Sciences, India
Frequently Asked Questions
Who can join the NCT07685353 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Liver Disease and Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07685353 currently recruiting?
Yes, NCT07685353 is actively recruiting participants. Contact the research team at bearebel69@gmail.com for enrollment information.
Where is the NCT07685353 trial being conducted?
This trial is being conducted at New Delhi, India.
Who is sponsoring the NCT07685353 clinical trial?
NCT07685353 is sponsored by Institute of Liver and Biliary Sciences, India. The principal investigator is Viniyendra Pamecha, MS, FEBS at Institute of Liver and Biliary Sciences, India. The trial plans to enroll 50 participants.